scholarly journals Effects of Recombinant Human Growth Hormone for 1 Year on Body Composition and Muscle Strength in Children on Long-Term Steroid Therapy: Randomized Controlled, Delayed-Start Study

2013 ◽  
Vol 98 (7) ◽  
pp. 2746-2754 ◽  
Author(s):  
Dominique Simon ◽  
Corinne Alberti ◽  
Marianne Alison ◽  
Loïc Le Henaff ◽  
Didier Chevenne ◽  
...  
Keyword(s):  
Body Composition ◽  
Muscle Strength ◽  
Recombinant Human Growth Hormone ◽  
Composite Index ◽  
Human Growth ◽  
Thigh Muscle ◽  
Muscle Area ◽  
Rhgh Therapy ◽  
Randomized Controlled

Context: Recombinant human GH (rhGH) improves growth and body composition in glucocorticoid-treated children. Its effects on muscle strength are poorly evaluated. Objectives: Our objective was to evaluate rhGH effects on muscle strength in children receiving long-term glucocorticoid therapy; effects on height SD score (SDS) and body composition were assessed also. Design and Setting: A randomized, controlled, delayed-start study of rhGH for 12 months was started after randomization (baseline) or 6 months later (M6). Patients: Patients included 30 children with various diagnoses. Intervention: rhGH was administered at 0.065 mg/kg/d for 6 months and then in the dosage maintaining serum IGF-I levels below +2 SDS for chronological age. Main Outcome Measures: The primary criterion was the between-group difference in composite index of muscle strength (CIMS) change at M6. Secondary criteria included between-group differences in CIMS SDSheight, lean mass (LM), thigh muscle area (MA), and height SDS changes at M6; these parameters were also assessed in the overall population after 1 year of rhGH therapy. Results: At M6, rhGH therapy did not significantly affect changes in CIMS or CIMS SDSheight (+17.6% vs +7.5% and +0.14 ± 0.38 vs +0.11 ± 0.62, respectively); the rhGH-treated group had significantly larger changes in height SDS (+0.2 [0.3] vs −0.2 [0.3]; P = 0.003), LM (+7.3% [+3.7%; +21.6%] vs 0% [−4.7%; +3.2%]; P = 0.002), and MA (+8.8% [+5%; +15.6%] vs. −0.6% [−6.3%; +7.7%]; P = 0.01) compared with the untreated group. After 1 year of rhGH, height SDS, LM, and MA increased significantly, CIMS increased by 24.7% (+5.8%; +34.2%), and CIMS SDSheight remained within the normal range. Conclusions: rhGH increased height, LM, and MA. However, muscle strength did not improve significantly.

scholarly journals Decreased Thyroxine Levels during rhGH Therapy in Children with Growth Hormone Deficiency

2021 ◽  
Vol 10 (21) ◽  
pp. 5100
Author(s):  
Ewelina Witkowska-Sędek ◽  
Anna Małgorzata Kucharska ◽  
Małgorzata Rumińska ◽  
Monika Paluchowska ◽  
Beata Pyrżak
Keyword(s):  
Growth Hormone ◽  
Thyroid Function ◽  
Growth Response ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Bone Age ◽  
Hormone Deficiency ◽  
Lower Growth ◽  
Rhgh Therapy

Background: Hypothyroidism in children leads to growth retardation. However, there is some evidence that recombinant human growth hormone (rhGH) therapy could suppress thyroid function. The most common observation in rhGH-treated patients is a decrease in thyroxine levels, which is reported as transient, but the studies in the field are inconsistent. We aimed to evaluate thyroid function in initially euthyroid children with idiopathic isolated GH deficiency during long-term rhGH therapy and to determine who is at a higher risk of thyroid function alterations during the therapy. Methods: The study group consisted of 101 children treated with rhGH for at least three years. Serum TSH and fT4 levels were determined at baseline, after the first six months and after each full year of therapy. The associations between changes in thyroid hormone levels during rhGH therapy and GH deficit, insulin-like growth factor-1 levels and growth response were investigated. Results: A significant decrease in fT4 levels (p = 0.01) was found as early as after the first six months of rhGH therapy. This effect persisted in the subsequent years of treatment without any significant changes in TSH values and tended to be rhGH dose related. Children with a greater fT4 decrease after the initiation of rhGH therapy were older, had higher bone age and responded to that therapy worse than children with lower fT4 changes. Conclusions: Our study revealed a long-term decrease in fT4 levels during rhGH therapy in initially euthyroid GHD children. The decrease in fT4 levels was associated with a lower growth response to rhGH therapy.

scholarly journals Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy

2013 ◽  
Vol 98 (1) ◽  
pp. 352-361 ◽  
Author(s):  
Kim M. J. A. Claessen ◽  
Natasha M. Appelman-Dijkstra ◽  
Desirée M. M. M. Adoptie ◽  
Ferdinand Roelfsema ◽  
Johannes W. A. Smit ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Metabolic Profile ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Rhgh Therapy

scholarly journals Leukocyte and Skeletal Muscle Telomere Length and Body Composition in Monozygotic Twin Pairs Discordant for Long-term Hormone Replacement Therapy

2017 ◽  
Vol 20 (2) ◽  
pp. 119-131 ◽  
Author(s):  
Elina Sillanpää ◽  
Paula Niskala ◽  
Eija K. Laakkonen ◽  
Elodie Ponsot ◽  
Markku Alén ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Telomere Length ◽  
Hormone Replacement ◽  
Monozygotic Twin ◽  
Fat Free Mass ◽  
Thigh Muscle ◽  
Muscle Area

Estrogen-based hormone replacement therapy (HRT) may be associated with deceleration of cellular aging. We investigated whether long-term HRT has effects on leukocyte (LTL) or mean and minimum skeletal muscle telomere length (SMTL) in a design that controls for genotype and childhood environment. Associations between telomeres, body composition, and physical performance were also examined. Eleven monozygotic twin pairs (age 57.6 ± 1.8 years) discordant for HRT were studied. Mean duration of HRT use was 7.3 ± 3.7 years in the user sister, while their co-twins had never used HRT. LTL was measured by qPCR and SMTLs by southern blot. Body and muscle composition were estimated by bioimpedance and computed tomography, respectively. Physical performance was measured by jumping height and grip strength. HRT users and non-users did not differ in LTL or mean or minimum SMTL. Within-pair correlations were high in LTL (r= 0.69,p= .020) and in mean (r= 0.74,p= .014) and minimum SMTL (r= 0.88,p= .001). Body composition and performance were better in users than non-users. In analyses of individuals, LTL was associated with BMI (r2= 0.30,p= .030), percentage total body (r2= 0.43,p= .014), and thigh (r2= 0.55,p= .004) fat, while minimum SMTL was associated with fat-free mass (r2= 0.27,p= .020) and thigh muscle area (r2= 0.42,p= .016). We found no associations between HRT use and telomere length. Longer LTLs were associated with lower total and regional fat, while longer minimum SMTLs were associated with higher fat-free mass and greater thigh muscle area. This suggests that telomeres measured from different tissues may have different associations with measures of body composition.

Treatment with oxandrolone and the durability of effects in older men

2004 ◽  
Vol 96 (3) ◽  
pp. 1055-1062 ◽  
Author(s):  
E. Todd Schroeder ◽  
Ling Zheng ◽  
Kevin E. Yarasheski ◽  
Dajun Qian ◽  
Yolanda Stewart ◽  
...  
Keyword(s):  
Body Composition ◽  
Muscle Strength ◽  
Muscle Size ◽  
Thigh Muscle ◽  
Whole Body ◽  
Muscle Area ◽  
Leg Flexion ◽  
Anabolic Androgen ◽  
Total Body ◽  
Proximal Thigh

We investigated the effects of the anabolic androgen, oxandrolone, on lean body mass (LBM), muscle size, fat, and maximum voluntary muscle strength, and we determined the durability of effects after treatment was stopped. Thirty-two healthy 60- to 87-yr-old men were randomized to receive 20 mg oxandrolone/day ( n = 20) or placebo ( n = 12) for 12 wk. Body composition [dual-energy X-ray absorptiometry (DEXA), magnetic resonance imaging, and 2H2O dilution] and muscle strength [1 repetition maximum (1 RM)] were evaluated at baseline and after 12 wk of treatment; body composition (DEXA) and 1-RM strength were then assessed 12 wk after treatment was discontinued ( week 24). At week 12, oxandrolone increased LBM by 3.0 ± 1.5 kg ( P < 0.001), total body water by 2.9 ± 3.7 kg ( P = 0.002), and proximal thigh muscle area by 12.4 ± 8.4 cm2 ( P < 0.001); these increases were greater ( P < 0.003) than in the placebo group. Oxandrolone increased 1-RM strength for leg press by 6.7 ± 6.4% ( P < 0.001), leg flexion by 7.0 ± 7.8% ( P < 0.001), chest press by 9.3 ± 6.7% ( P < 0.001), and latissimus pull-down exercises by 5.1 ± 9.1% ( P = 0.02); these increases were greater than placebo. Oxandrolone reduced total (-1.9 ± 1.0 kg) and trunk fat (-1.3 ± 0.6 kg; P < 0.001), and these decreases were greater ( P < 0.001) than placebo. Twelve weeks after oxandrolone was discontinued ( week 24), the increments in LBM and muscle strength were no longer different from baseline ( P > 0.15). However, the decreases in total and trunk fat were sustained (-1.5 ± 1.8, P = 0.001 and -1.0 ± 1.1 kg, P < 0.001, respectively). Thus oxandrolone induced short-term improvements in LBM, muscle area, and strength, while reducing whole body and trunk adiposity. Anabolic improvements were lost 12 wk after discontinuing oxandrolone, whereas improvements in fat mass were largely sustained.

scholarly journals Body Composition by CT vs. DXA: Long-Term Prediction of Mortality in the Health Health ABC Cohort

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 239-239
Author(s):  
Samaneh Farsijani ◽  
Lingshu Xue ◽  
Robert Boudreau ◽  
Adam Santanasto ◽  
Stephen Kritchevsky ◽  
...  
Keyword(s):  
Body Composition ◽  
Fat Mass ◽  
Mortality Risk ◽  
Subcutaneous Fat ◽  
Thigh Muscle ◽  
Muscle Area ◽  
Muscle Density ◽  
Long Term Follow Up

Abstract Background: Early work in the Health ABC cohort found that strength, but not muscle size predicted mortality. Recent literature suggests that body composition by computerized tomography (CT) and magnetic resonance imaging (MRI) predicts adverse health outcomes in diverse populations, but has not been directly compared to dual-energy X-ray absorptiometry (DXA) for predicting mortality. Objective: With long term follow-up, we reexamined body composition and mortality in Health ABC, comparing DXA and CT measures of muscle and fat. Methods: The Health ABC study assessed body composition in 2911 older adults (age 73.6±2.9 years) in 1996-97. Mid-thigh CTs were read for muscle area, inter-muscular, subcutaneous-fat areas and muscle density (HU). DXAs were read for whole body fat mass and appendicular lean mass (ALM). Mortality was assessed every 6-months through 2014 (maximum 17.4 years). Cox proportional hazards models, adjusting for age, sex, race, height, weight, physical activity, smoking and comorbidities were used to assess mortality risk. Results: Strong correlations were observed between mid-thigh muscle and subcutaneous fat areas by CT and leg lean and fat mass by DXA (P&lt;0.05). Lower mortality rates, per SD, were associated with higher CT muscle area (HR-men=0.76 [95%CI: 0.68-0.86]; HR-women=0.84 [0.75-0.94]), muscle density (HR-men=0.86 [0.79-0.93]; HR-women=0.89 [0.81-0.97]) and higher subcutaneous-fat (HR-men=0.90 [0.81-0.99]; HR-women=0.87 [0.77-0.98]), adjusting for covariates. Similarly for DXA, greater ALM (HR-men=0.56 [0.44-0.71]; HR-women=0.77 [0.59-1.01]) and higher total fat mass (HR-men=0.53 [0.40-0.72]; HR-women=0.58 [0.37-0.90]) were associated with lower risk of death. Conclusion: With long term follow-up, both CT and DXA assessments of body composition predicted all-cause mortality risk.

scholarly journals Effects of Two Months of Very Low Carbohydrate Ketogenic Diet on Body Composition, Muscle Strength, Muscle Area, and Blood Parameters in Competitive Natural Body Builders

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 374
Author(s):  
Antonio Paoli ◽  
Lorenzo Cenci ◽  
PierLuigi Pompei ◽  
Nese Sahin ◽  
Antonino Bianco ◽  
...  
Keyword(s):  
Body Composition ◽  
Muscle Strength ◽  
Ketogenic Diet ◽  
Inflammatory Cytokines ◽  
Blood Parameters ◽  
Maximal Strength ◽  
Muscle Area ◽  
Low Carbohydrate ◽  
Before And After ◽  
Adequate Quantity

Background: Ketogenic diet (KD) is a nutritional approach that restricts daily carbohydrates, replacing most of the reduced energy with fat, while maintaining an adequate quantity of protein. Despite the widespread use of KD in weight loss in athletes, there are still many concerns about its use in sports requiring muscle mass accrual. Thus, the present study sought to investigate the influence of a KD in competitive natural body builders. Methods: Nineteen volunteers (27.4 ± 10.5 years) were randomly assigned to ketogenic diet (KD) or to a western diet (WD). Body composition, muscle strength and basal metabolic rate were measured before and after two months of intervention. Standard blood biochemistry, testosterone, IGF-1, brain-derived neurotrophic factor (BDNF) and inflammatory cytokines (IL6, IL1β, TNFα) were also measured. Results: Body fat significantly decreased in KD (p = 0.030); whilst lean mass increased significantly only in WD (p < 0.001). Maximal strength increased similarly in both groups. KD showed a significant decrease of blood triglycerides (p < 0.001), glucose (p = 0.001), insulin (p < 0.001) and inflammatory cytokines compared to WD whilst BDNF increased in both groups with significant greater changes in KD (p < 0.001). Conclusions: KD may be used during body building preparation for health and leaning purposes but with the caution that hypertrophic muscle response could be blunted.

Sign in / Sign up

Export Citation Format

Share Document